Business
QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025.
About this update from Quidelortho Corporation
[{"type":"text","content":"― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ―","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ―","length":115,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025.","length":281,"tagName":"p"},{"type":"image","alt":"QuidelOrtho Corporation (PRNewsfoto/QuidelOrtho Corporation)","displaySize":"","headline":null,"caption":"QuidelOrtho Corporation (PRNewsfoto/QuidelOrtho Corporation)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":49,"url":"https://media.zenfs.com/en/prnewswire.com/3ada073b617e5b803ac84b350e702145"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kuYGAKfWp.t5F8.Stk9v7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTg2O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/3ada073b617e5b803ac84b350e702145","width":400,"height":49}},"href":"https://mma.prnewswire.com/media/2838981/QuidelOrtho_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagnostics business," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. "Our Labs, Immunohematology and Cardiac businesses delivered consistent growth, while cost-savings initiatives drove meaningful margin expansion. As a result, we are well positioned to generate substantially stronger free cash flow in 2026, which we believe more accurately reflects the earnings power of our business."","length":524,"tagName":"p"},{"type":"text","content":"Key Fourth Quarter 2025 Results:(all comparisons are to the prior year period)","length":79,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue was $724 million, as reported","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Non-respiratory revenue of $600 million; excluding Donor Screening1, non-respiratory re...